Mer­ck de­tails win for Keytru­da in blad­der can­cer af­ter surgery

Mer­ck’s top-sell­ing can­cer drug Keytru­da cut the risk of blad­der can­cer com­ing back or death af­ter surgery by 31%, ac­cord­ing to new da­ta shared Fri­day morn­ing.

The Phase III study, known as AM­BAS­SADOR or KEYNOTE-123, in­clud­ed just over 700 pa­tients with urothe­lial car­ci­no­ma — the most com­mon type of blad­der can­cer — who were con­sid­ered at high risk for re­lapse fol­low­ing surgery. The pa­tients re­ceived Keytru­da for a year af­ter their pro­ce­dure or were ob­served with­out a place­bo pill.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER